Contact Information: Contact: Ralph Barry Chief Business Officer Aegis Therapeutics LLC 1-858-618-1400 Ext. 102 Email: Email Contact
Aegis Therapeutics to Present at the "C21 BioVentures Conference" in Monterey California in May 2007
| Source: Aegis Therapeutics LLC
SAN DIEGO, CA -- (MARKET WIRE) -- April 4, 2007 -- Aegis Therapeutics, a drug delivery
technology licensing company and leader in transmucosal drug delivery, will
present its recently formed Cedar Therapeutics Inc. spin-out company at the
C21 BioVentures Conference to be held at the Monterey Plaza Hotel and Spa,
Monterey, CA May 22-24, 2007. Cedar Therapeutics was formed to develop
novel, proprietary, and superior formulations for certain drugs recently or
soon-to-be off-patent addressing a current total market in excess of $11
Billion and eligible for FDA 505(b)2 accelerated regulatory treatment using
Aegis' proprietary Intravail® and ProTek® advanced proprietary drug
delivery and formulation technologies.
Information about the conference may be obtained from the following
website: http://www.techvision.com/c21/pdf/c21_brochure.pdf
About Aegis Therapeutics
Aegis Therapeutics LLC is a drug delivery technology company
commercializing its patented or proprietary drug delivery and drug
formulation technologies through product-specific licenses. Our
Intravail® drug delivery technology enables the non-invasive delivery of
a broad range of protein, peptide and non-peptide macromolecular
therapeutics that can currently only be administered by injection. Aegis'
Intravail® absorption enhancement agents provide exceptionally high and
unmatched bioavailability performance, comparable in efficiency to
subcutaneous injection, via the intranasal and other mucosal membrane
administration routes. Our ProTek® technology allows creation of
proprietary, easily manufacturable, and stable aqueous or lyophilized
dosage forms that maintain the integrity and physiological activity of many
protein and peptide therapeutics. ProTek® technology is applicable to
injectable, intranasal, and other dosage forms of peptide or protein
therapeutics.
For more information about Aegis, please visit the Aegis website
at: http://www.aegisthera.com.